American Society for Blood and Marrow Transplantation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2016
NCT02494167
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

American Society for Blood and Marrow Transplantation (ASBMT)

Active Ingredients

Drugs in Phase 1 Trials (1)

multitaa t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1